Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
Autore:
Fry, J; Scharf, M; Mangano, R; Fujimori, M;
Indirizzi:
Med Coll Penn & Hahnemann Univ, Sleep Disorders Ctr, Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ Philadelphia PA USA 19129 ia, PA 19129 USA Ctr Sleep Disorders, Cincinnati, OH USA Ctr Sleep Disorders Cincinnati OHUSA leep Disorders, Cincinnati, OH USA Wyeth Ayerst Res, Radnor, PA USA Wyeth Ayerst Res Radnor PA USAWyeth Ayerst Res, Radnor, PA USA
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 15, anno: 2000,
pagine: 141 - 152
SICI:
0268-1315(200005)15:3<141:ZISWPR>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ZOLPIDEM; PLACEBO; PHARMACOKINETICS; PHARMACODYNAMICS; PREVALENCE; EFFICACY; SINGLE; MEMORY;
Keywords:
insomnia; zaleplon; hypnotic; rebound insomnia; tolerance; withdrawal;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Fry, J Med Coll Penn & Hahnemann Univ, Sleep Disorders Ctr, 3200 Henry Ave, Philadelphia, PA 19129 USA Med Coll Penn & Hahnemann Univ 3200 Henry Ave Philadelphia PA USA 19129
Citazione:
J. Fry et al., "Zaleplon improves sleep without producing rebound effects in outpatients with insomnia", INT CLIN PS, 15(3), 2000, pp. 141-152

Abstract

The efficacy and safety of three doses of zaleplon, a novel non-henzodiazepine hypnotic, were compared with those of placebo in outpatients with insomnia in this l-week study, using zolpidem 10 mg as active comparator. Postsleep questionnaires were used to determine treatment effects on the patient's perception of sleep, as well as any development of pharmacological tolerance during therapy or rebound insomnia or withdrawal symptoms upon discontinuation of therapy. During week 1, sleep latency was significantly shorterwith zaleplon 5, 10, and 20 mg compared to placebo. The significant decrease in sleep latency persisted through week 4 with zaleplon 20 mg, and was again evident with zaleplon 10 mg at week 3. Zaleplon 20 mg also had significant effects on sleep duration, number of awakenings, and sleep quality compared to placebo. No pharmacological tolerance developed during treatment with zaleplon and there were no indications of rebound insomnia or withdrawal symptoms after treatment discontinuation. Zolpidem 10 mg had significant effects on sleep latency, sleep duration, and sleep quality compared to placebo. However, a significantly greater incidence of withdrawal symptoms anda suggestion of sleep difficulty after treatment discontinuation (rebound insomnia) for all sleep measures was seen with zolpidem compared to placebo. There was no significant difference in the frequency of adverse events with active treatment compared to placebo. These results show that zaleplon provides effective treatment of insomnia with a favourable safety profile. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:26:24